Cleveland Clinic breast radiologist, Laura Dean, MD, to
discuss how iCAD’s Breast AI Suite helps her detect the breast cancers
radiologists fear most


NASHUA, N.H., July 12, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced its “ProFound Insights, ProFound Impact” webinar series will feature Dr.
Laura Dean, a renowned breast radiologist at the Cleveland Clinic. Titled “How Cleveland Clinic is
Finding the Breast Cancers Radiologists Fear the Most,” the live event
will take place on Thursday, July 20 at 10 am ET. The event will be moderated
by iCAD’s President and CEO, Dana Brown. To register, visit this


“iCAD’s Breast AI Suite
is revolutionizing breast cancer screening. Our cutting-edge technology not
only elevates the skills of the nation’s top radiologists but also reinforces
their excellence,” commented Dana Brown, President and CEO of iCAD, Inc. “We look
forward to showcasing Dr. Dean in this compelling event, where she will provide
valuable insights from her clinical experience, share best practices, and
present compelling case studies that highlight the distinctive workflow
advantages and unique value our technologies offer to clinicians, facilities,
and patients.”


During the event, Dr. Dean will discuss how she leverages
iCAD’s market-leading technology to detect breast cancers, including small,
subtle tumors – the types of cancers radiologists fear the most. She will also
present a live clinical case review showcasing how ProFound AI® can enhance
cancer detection in a clinical setting.


“Even for experienced radiologists, some findings
are so subtle they can be difficult to detect,” said Dr. Dean. “ProFound AI
acts as an extra set of eyes that empowers our team to catch even the smallest,
most difficult-to-detect cancers – and with greater accuracy than ever. This
reliable, game-changing technology not only improves our confidence, it
optimizes efficiency and improves patient outcomes.”


ProFound AI became the first technology of its kind to be
FDA cleared in 2018. Built with the latest in deep-learning artificial
intelligence, ProFound AI is clinically proven to improve radiologists’
sensitivity by 8%, reduce the rate of false positives and unnecessary callbacks
by 7%, and slash reading time by more than half.[1]


Launched last
, the “ProFound Insights, ProFound Impact” webinar series has featured
a number of esteemed clinical, IT, and administrative experts, along with
customer success stories and impactful case studies from healthcare facilities around
the globe. Previous event recordings are available on the Company’s website,


About iCAD, Inc.

Headquartered in Nashua, NH, iCAD® is a global medical
technology leader providing innovative cancer detection and therapy solutions.
For more information, visit


Forward-Looking Statements

Certain statements contained in this News Release
constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements about the
expansion of access to the Company’s products, improvement of performance,
acceleration of adoption, expected benefits of ProFound AI®, the benefits of
the Company’s products, and future prospects for the Company’s technology
platforms and products. Such forward-looking statements involve a number of
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance, or achievements of the Company to be materially
different from any future results, performance, or achievements expressed or
implied by such forward-looking statements. Such factors include, but are not
limited, to the Company’s ability to achieve business and strategic objectives,
the willingness of patients to undergo mammography screening in light of risks
of potential exposure to Covid-19, whether mammography screening will be
treated as an essential procedure, whether ProFound AI will improve reading
efficiency, improve specificity and sensitivity, reduce false positives and
otherwise prove to be more beneficial for patients and clinicians, the impact
of supply and manufacturing constraints or difficulties on our ability to
fulfill our orders, uncertainty of future sales levels, to defend itself in
litigation matters, protection of patents and other proprietary rights, product
market acceptance, possible technological obsolescence of products, increased
competition, government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt obligations,
competitive factors, the effects of a decline in the economy or markets served
by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,” “demonstrate,”
“intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,”
“seek,” and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website at and on the SEC’s website at




Media Inquiries:

Jessica Burns, iCAD



Investor Inquiries:

iCAD Investor


[1] Conant,
E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of
Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial
Intelligence. 1 (4). Accessed via